logo
Plus   Neg
Share
Email

Lilly : Late-stage Lung Cancer Trial Meets Primary Endpoint Of Overall Survival

Eli Lilly and Co. (LLY) announced Wednesday that the REVEL trial, a global Phase III study of ramucirumab in combination with chemotherapy in patients with second-line non-small cell lung cancer or NSCLC, showed a statistically significant improvement in the primary endpoint of overall survival in the ramucirumab-plus-docetaxel arm compared to the control arm of placebo plus docetaxel.

REVEL also showed a statistically significant improvement in progression-free survival in the ramucirumab arm compared to the control arm.

The global, randomized, double-blind REVEL trial compared ramucirumab and docetaxel to placebo and docetaxel in NSCLC patients whose disease has progressed after failure of prior platinum-based chemotherapy for locally advanced or metastatic disease. The study included nonsquamous and squamous NSCLC patients. The most common (>5% incidence) Grade >3 adverse events occurring at a higher rate on the ramucirumab-plus-docetaxel arm compared to the control arm were decreased white blood cell count (neutropenia/leukopenia), febrile neutropenia, fatigue/asthenia and hypertension.

Lilly said it plans to present data from the REVEL trial at an upcoming scientific meeting and intends to submit the first application of these data to regulatory authorities in 2014.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A 30-year GE veteran, top man Flannery is no run-of-the-mill guy. When he assumed leadership of the struggling GE Healthcare business in 2014, the general consensus was he would spin-off or sell the segment, but he did neither. Today, Healthcare is one of the strongest arms of GE, and a notable player in the production of cell therapies and biologics - the cutting-edge of biomedical research. With sales by online retailers accounting for an increasing share of consumer spending, the U.S. Supreme Court has handed states a major victory in their efforts to boost revenue from sales tax. In a 5 to 4 ruling published Thursday, the Supreme Court sided with South Dakota in a case against online... AT&T Inc., which recently completed its acquisition of Time Warner Inc., has launched its new "WatchTV" streaming service with two unlimited data plans. In addition, WatchTV can be streamed through the WatchTV app. The two data plans - AT&T Unlimited &More and AT&T Unlimited &More Premium - are scheduled to launch next week. WatchTV features more than 30 live channels.
Follow RTT